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Prompt restoration of coronary arterial blood flow has been
the cornerstone of successful therapy for acute ST-segment
elevation myocardial infarction (MI) for the past two
decades. Data from randomized clinical trials (1) coupled
with parallel angiographic studies have provided unequivo-
cal proof that achievement of myocardial reperfusion is
largely responsible for the observed health benefits (2,3). In
addition, the “time-dependent” impact of fibrinolytic ther-
apy (4) has been demonstrated consistently and provides
incontrovertible support for increased patient survival, de-
creased infarct size, and improved left ventricular perfor-
mance with early successful reperfusion. Accordingly, the
National Heart Attack Alert Program and other broad-
based health care initiatives were developed to rapidly
identify and treat patients with acute MI (5).
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During the past decade, primary angioplasty has emerged
as an attractive means to restore coronary arterial blood flow
and myocardial perfusion among patients with ST-segment
elevation MI. Clinical trials comparing pharmacologic and
mechanical modalities of reperfusion have convincingly
demonstrated that the latter more effectively achieves the
objectives of treatment with a lower risk of major hemor-
rhage (6,7). This advantage translates to improvements in
clinical outcomes, at least in the clinical trial setting.
Patients undergoing primary angioplasty in the Primary
Angioplasty in Myocardial Infarction (PAMI) trial were less
likely to die or experience re-infarction than those receiving
fibrinolytic therapy (5.1% vs. 12.0%) (6). Similarly, in
Global Use of Strategies to Open Occluded Coronary
Arteries in Acute Coronary Syndromes (GUSTO-IIb),
patients undergoing primary angioplasty had a lower risk of
death, MI, or stroke at 30 days than those receiving alteplase
(9.6% vs. 13.6%) (7). Although these data have generated
considerable enthusiasm for the use of primary angioplasty
for ST-elevation MI, the question has been raised whether
the results achieved by the high-volume centers offering
round-the-clock services and employing experienced staff
can be replicated in day-to-day practice. For example,
in-hospital death rates for patients enrolled in the National
Registry of Myocardial Infarction (NRMI) were similar for
each reperfusion modality (primary angioplasty 5.2%, fi-
brinolytics 5.4%) (8). Other registries have made similar
observations.
The contrasting outcomes for patients treated in large
tertiary medical centers within the carefully defined con-
struct of a clinical trial and daily practice in community
hospitals are likely due to several factors. Catheterization
laboratory volume, operator experience, and differing use of
adjunctive therapies have each been shown to impact patient
outcome (9,10). In addition, most observational studies
suggest that the efficacy of primary angioplasty, as with
fibrinolytic therapy, is time-dependent. In a study of 1,352
patients undergoing primary angioplasty at a single center,
those in whom reperfusion was achieved in 2 h from
symptom onset had markedly decreased 30-day mortality
rates compared to those in whom reperfusion occurred
beyond 2 h (4.3% vs. 9.2%) (11). Data from the NRMI-2
suggest a 40% to 60% increase in hospital mortality with
door-to-balloon times in excess of 2 h (12).
Unfortunately delays in reperfusion are not unexpected,
particularly for patients presenting to the hospital at night.
In the NRMI-2, median time to first balloon inflation was
111 min, compared with 42 min for initiation of fibrinolytic
treatment (door-to-needle) (13). Data from the same reg-
istry identified non-daytime presentation as one of the
strongest predictors of door-to-balloon times 2 h. These
data serve as the basis for current American College of
Cardiology/American Heart Association (ACC/AHA)
guidelines (14) that recommend door-to-balloon times of
90 min for primary angioplasty and encourage a concerted
effort by institutions to ensure prompt treatment of patients
with MI regardless of time of presentation.
In this issue of the Journal, the study by Henriques et al.
(15) is of particular interest and relevance for national and
international health care directives. Using data from 1,702
consecutive patients referred to a single center with acute
ST-elevation MI, the investigators identified a difference in
angioplasty success rates based on times of treatment. This
was associated with a two-fold increase in 30-day mortality
for patients admitted “off hours” (4.2% vs. 1.9%). Interest-
ingly, and reflective of this center’s dedication to “round-
the-clock” primary angioplasty, time to first balloon infla-
tion was not significantly different by time of presentation
(8:00 AM to 6:00 PM, 64 min vs. 6:00 PM to 8:00 AM, 69
min). These data suggest that the “time of treatment” is
independent of “time to treatment” and collectively deter-
mines the benefit of mechanical reperfusion.
An explanation for the observed “circadian variation” in
efficacy for primary angioplasty is not readily apparent. As
suggested by the investigators, differing outcomes based on
time of treatment may be linked to circadian variations in
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the pathobiology of atheromatous plaque rupture and local-
ized thrombosis. Platelet aggregation in response to epi-
nephrine, adenosine diphosphate, and thrombin is height-
ened during the early morning hours, particularly after
arising from sleep (16,17). The plasma level of fibrinogen
increases steadily between 6 AM and 12 PM, whereas anti-
thrombin levels decline (16). Similarly, several investigators
have described a circadian variation or periodicity in fibrino-
lytic activity and thrombus lysability. Andreotti et al. (18)
reported major circadian fluctuations in fibrinolytic factors,
with a marked peak in plasminogen activator inhibitor
activity during the early morning hours. Consistent with
platelet biology and coagulation protease activity, a “pro-
thrombotic period” exists between 6 AM and 12 PM and is
independent of physical activity, work schedule, and/or
sleep patterns. Epidemiologic data provide further support
of periodicity, with an early morning peak in the occurrence
of angina, MI, and sudden death (19,20).
The impact of pathobiologic periodicity on response to
treatment in patients with MI has been studied. Using data
from the Physician’s Health Study, Ridker et al. (20) noted
a bimodal distribution of MI onset, with a primary peak in
the morning hours in patients treated with placebo. This
morning peak was decreased by 60% in patients receiving
alternate-day aspirin, in essence eliminating any circadian
variation in MI onset. Although the anticoagulant effects of
a continuous heparin infusion appear to follow a circadian
variation, the clinical significance of this has not been
established (21). Finally, a diurnal variation in response to
fibrinolytic therapy has also been documented. In a study of
244 patients with MI treated with either urokinase or tissue
plasminogen activator, resistance to fibrinolytics was ob-
served in the early morning and late evening hours (22).
Although it is an interesting hypothesis to consider, it
seems unlikely that circadian variations in either thrombotic
propensity or platelet behavior strongly contribute to the
findings of Henriques et al. (15). The existence of circadian
variation in a number of physiologic pathways, particularly
platelet aggregation, cause thrombotic potential in the early
morning hours. Accordingly, it is difficult to link heightened
platelet activatability with the efficacy of angioplasty per-
formed at night. Second, although intrinsic fibrinolytic
capacity could be influenced by circadian variation in plate-
let or thrombotic activity, it is more challenging to postulate
a link between these events and failure of initial mechanical
revascularization. If either pathway were operational, one
would have possibly expected recurrent thrombosis, MI, or
sudden death following initial angioplasty; however, these
outcomes were not reported. In addition, the administration
of aspirin and heparin to all patients before their procedure
would have minimized the impact of circadian variations in
prothrombotic propensity.
On the basis of the available information, it seems much
more likely that differences in outcomes observed in this
study are accounted for by variations in patient characteris-
tics, their care-seeking patterns, and/or the administered
processes of care. Although baseline demographic and
clinical characteristics stratified by time of presentation
failed to reveal statistically significant differences in the
variables measured, other nonreported factors may have
been influential. Nearly one-half of the patients were
referred from outside hospitals. It is possible that triage
decisions varied by time of day and, as a result, more
inherently ill or complex patients were transferred for
angioplasty while others remained at community hospitals
for fibrinolytic and/or medical treatment. The investigators
acknowledge that patients presenting at night may have
longer delay times from MI onset to presentation, even
though symptom onset to admission did not differ signifi-
cantly by time of day in their study (8:00 AM to 6 PM, 143
min vs. 6 PM to 8 AM, 146 min). Information derived from
other observational studies suggests this may be the case.
Data abstracted from the medical records of 1,255 patients
with validated MI enrolled in the Worcester Heart Attack
Study between 1995 and 1997 show marked differences in
“pre-hospital” delay for patients presenting at different times
of the day (23). Patients presenting from 12 AM to 6 AM
delayed 1.4 h longer (mean pre-hospital delay 5.5 h) than
those presenting from 6 AM to 12 PM. Onset of symptoms in
the nighttime hours was significantly associated with delays
of 2 h. These differences could certainly impact reperfu-
sion success rates and clinical outcomes. Similarly, although
the single site experience described in the current study
employed 24-h services and achieved short time delays, the
investigators appropriately acknowledge that other poten-
tially important variables in patient care delivery could be
impacted by time of day. Timely utilization of adjunctive
therapies might also differ by time of day. Unfortunately,
data on these and other treatment differences between
groups in the current study are not provided.
An important consideration for “off-hours” primary an-
gioplasty that is not commented on in the present study is
whether the performance and characteristics of the health
care team varies according to time of day. In most institu-
tions the cardiac catheterization laboratory team, including
the senior operators, work the daytime hours but take “call”
at night for emergencies. On any given night the health care
providers can be mildly to severely sleep deprived depending
on their call schedule, daytime activities, and the length/
intensity of prior shifts. The detrimental impacts of short-
term and/or chronic sleep deprivation on cognitive perfor-
mance and motor function are recognized and have been
studied in a variety of subjects including healthy volunteers,
truck drivers, and airline pilots. It has been estimated that
wakefulness for 24 h is equivalent to a blood alcohol level of
0.1% with respect to effect on cognitive performance (24).
As reviewed by Veasey et al. (25) in a recent issue of JAMA,
the effects of sleep deprivation have been particularly well
studied in medical residents in training. In one retrospective
review of 6,371 surgical cases in which residents partici-
pated, 351 postoperative complications were identified (26).
Although there were no differences in outcome by call
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schedule type, complication rates were 45% higher for
residents on call the previous night. In another study of 14
surgical residents, speed and accuracy for simulated laparo-
scopic procedures suffered greatly after 17 h on call (average
sleep time 1.5 h) (27). These and other data suggest that
even brief periods of sleep deprivation can impair
procedure-related performance. A study of emergency de-
partment physicians found that night-shift physicians per-
formed poorly on simulated intubation and clinical triage
when compared with physicians working during the day
(28). Performance further deteriorated with continued night
shift duty. As residents on the night shift were documented
to have inadequate sleep during the day, it was suggested
that their worsening performance was due to sleep depriva-
tion as well as circadian variations in cognitive function and
manual dexterity. Surprisingly little if any attention has been
paid to the impact of sleep deprivation and/or circadian
variations on performance in other health care providers
(staff physicians, fellows, nurses, technicians). One should
consider strongly whether one or more of these factors
contributed to the current study’s findings. Although cur-
rent ACC/AHA guidelines stipulate that primary angio-
plasty must be performed by experienced operators (75
cases/year), in high-volume institutions (400 cases/year),
and in a timely fashion (door-to-balloon time 90 min),
there are no specific recommendations regarding nighttime
staffing, work schedules, or hours on call (14). Given that
many practicing interventionalists completed their training
before currently existing reforms for residency training, they
may feel that guidelines are unnecessary or perhaps even
obtrusive, yet they would likely agree that the cognitive and
technical demands for performing primary angioplasty are
substantial.
Given the burden of coronary heart disease worldwide,
and the exponential growth in the use of mechanical
revascularization, the data presented in the study by Hen-
riques et al. (15) warrant careful consideration. If, in fact,
procedural success rates and associated outcomes are influ-
enced by time of day, the investigators have brought to light
an important issue with substantial health care policy
implications. Further studies designed to evaluate circadian
variations in care-seeking behavior among patients with MI,
as well as the performance of the health care team treating
them, must be undertaken.
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